Physician profile
Constance C Blunt
NPI 1710245162
$3,652.94
in general payments reported to CMS, 2019-2025
45 companies · $983 in 2025
The $983 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $511 · 2020: $75.80 · 2021: $136 · 2022: $916 · 2023: $334 · 2024: $698 · 2025: $983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,971 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,971.39 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $470.68 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $338.05 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Amgen INC. | $266.80 | 2019-2022 | |
| Daiichi Sankyo INC. | $257.65 | 2021-2025 | Enhertu, Datroway |
| Novartis Pharmaceuticals Corporation | $237.12 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $161.67 | 2020-2025 | Enhertu, Calquence, Lynparza |
| Gilead Sciences, INC. | $145.92 | 2021-2025 | Trodelvy |
| Celgene Corporation | $134.86 | 2019-2023 | Pomalyst |
| Abbvie INC. | $133.85 | 2022-2025 | |
| Array Biopharma INC | $110.77 | 2024-2025 | Mektovi, Braftovi, Lorbrena |
| Eisai INC. | $103.66 | 2022 | |
| Tersera Therapeutics LLC | $97.66 | 2023-2025 | Zoladex |
| Pharmacyclics LLC, An Abbvie Company | $91.21 | 2021-2023 | Imbruvica |
| Beigene USA, INC. | $82.56 | 2021-2024 | Brukinsa |
| Genzyme Corporation | $71.41 | 2020-2025 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Constance Blunt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.